MTC

Molecular Targeting Technologies, Inc. (MTTI) is a clinical-stage biotechnology company specializing in the development of targeted radiotherapeutics and molecular imaging agents for rare cancers and infectious diseases. The company's core technology, the EvaThera platform, utilizes an Evans blue (EB)-based delivery system to enhance the half-life and tumor accumulation of therapeutic and diagnostic molecules. MTTI's lead clinical candidate, 177Lu-DOTA-EB-TATE, is currently being evaluated in Phase 1/2 trials for the treatment of neuroendocrine tumors. Additionally, the company maintains a diverse pipeline of imaging probes and research reagents, including the PSVue® and CellVue® product lines, which target biomarkers such as phosphatidylserine to detect cell death and infection.